Engaging Discussion: Fennec Pharmaceuticals at Investor Conference
Fennec Pharmaceuticals Set to Engage at Investor Conference
Fennec Pharmaceuticals Inc. (NASDAQ: FENC; TSX: FRX), a leader in specialty pharmaceuticals, has officially announced its participation in the H.C. Wainwright @ Home Fireside Chat Series. This virtual event, scheduled for December 16, is a great opportunity for investors to hear directly from company representatives about their recent achievements and future directions.
Availability of the Webcast
For those interested in tuning in, Fennec Pharmaceuticals will provide a live webcast of the session, which begins at 11:00 a.m. ET. After the event, an archived replay will be readily accessible on the Fennec website, ensuring that all stakeholders can catch up on what promises to be an enlightening discussion about the company's growth and strategy.
About Fennec Pharmaceuticals
Fennec Pharmaceuticals is committed to addressing critical health needs, particularly in pediatrics. Their flagship product, PEDMARK, is designed to mitigate the risk of platinum-induced ototoxicity in children being treated with chemotherapy. Since receiving FDA approval in September 2022, as well as additional approvals from the European Commission and U.K. regulatory bodies in 2023 for the brand PEDMARQSI, Fennec has made significant strides in the pharmaceutical landscape.
Recent Achievements
The approvals signify a crucial step for Fennec Pharmaceuticals, showcasing its dedication to enhancing treatment safety for young patients. PEDMARK's Orphan Drug Exclusivity in the U.S. further emphasizes its rare and vital role in pediatric oncology. Additionally, PEDMARQSI has received Pediatric Use Marketing Authorization in Europe, reinforcing the company’s foothold in key markets across the globe.
Contact Information
For inquiries related to investor relations, Robert Andrade, the Chief Financial Officer at Fennec Pharmaceuticals, is available at +1 919-246-5299. Meanwhile, for media and corporate questions, Lindsay Rocco from Elixir Health Public Relations can be reached at +1 862-596-1304 or via email.
Frequently Asked Questions
What is the main focus of Fennec Pharmaceuticals?
Fennec Pharmaceuticals focuses on developing and commercializing safe treatment options for pediatric patients, particularly in oncology.
When will the webcast for the investor conference be available?
The webcast will be live on December 16 at 11:00 a.m. ET, with an archived version available after the event on the Fennec website.
What is PEDMARK and why is it important?
PEDMARK is the first FDA-approved drug aimed at preventing platinum-induced ototoxicity in children undergoing chemotherapy, making it crucial for pediatric cancer care.
How does Fennec Pharmaceuticals ensure product efficacy?
Through rigorous clinical trials and regulatory approvals, Fennec Pharmaceuticals validates the effectiveness and safety of its products.
Who should I contact for more information about Fennec Pharmaceuticals?
For investor-related inquiries, contact Robert Andrade, and for media questions, reach out to Lindsay Rocco.
About Investors Hangout
Investors Hangout is a leading online stock forum for financial discussion and learning, offering a wide range of free tools and resources. It draws in traders of all levels, who exchange market knowledge, investigate trading tactics, and keep an eye on industry developments in real time. Featuring financial articles, stock message boards, quotes, charts, company profiles, and live news updates. Through cooperative learning and a wealth of informational resources, it helps users from novices creating their first portfolios to experts honing their techniques. Join Investors Hangout today: https://investorshangout.com/
Disclaimer: The content of this article is solely for general informational purposes only; it does not represent legal, financial, or investment advice. Investors Hangout does not offer financial advice; the author is not a licensed financial advisor. Consult a qualified advisor before making any financial or investment decisions based on this article. The author's interpretation of publicly available data shapes the opinions presented here; as a result, they should not be taken as advice to purchase, sell, or hold any securities mentioned or any other investments. The author does not guarantee the accuracy, completeness, or timeliness of any material, providing it "as is." Information and market conditions may change; past performance is not indicative of future outcomes. If any of the material offered here is inaccurate, please contact us for corrections.